Related Experiment Video
Updated: Nov 16, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature
Ke Chen1, Xiao Wang2, Liu Yang2
1Department of Gastrointestinal and Pancreatic Surgery, 74678Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
Background:
Treatment options for advanced gastric esophageal cancer are quite limited. Chemotherapy is unavoidable at certain stages, and research on targeted therapies has mostly failed. The advent of immunotherapy has brought hope for the treatment of advanced gastric esophageal cancer. The aim of the study was to analyze the safety of anti-PD-1/PD-L1 immunotherapy and the long-term survival of patients who were diagnosed as gastric esophageal cancer and received anti-PD-1/PD-L1 immunotherapy.
Method:
Studies on anti-PD-1/PD-L1 immunotherapy of advanced gastric esophageal cancer published before February 1, 2020 were searched online. The survival (e.g. 6-month overall survival, 12-month overall survival (OS), progression-free survival (PFS), objective response rates (ORR)) and adverse effects of immunotherapy were compared to that of control therapy (physician's choice of therapy).
Results:
After screening 185 studies, 4 comparative cohort studies which reported the long-term survival of patients receiving immunotherapy were included. Compared to control group, the 12-month survival (OR = 1.67, 95% CI: 1.31 to 2.12, P < 0.0001) and 18-month survival (OR = 1.98, 95% CI: 1.39 to 2.81, P = 0.0001) were significantly longer in immunotherapy group. The 3-month survival rate (OR = 1.05, 95% CI: 0.36 to 3.06, P = 0.92) and 18-month survival rate (OR = 1.44, 95% CI: 0.98 to 2.12, P = 0.07) were not significantly different between immunotherapy group and control group. The ORR were not significantly different between immunotherapy group and control group (OR = 1.54, 95% CI: 0.65 to 3.66, P = 0.01). Meta-analysis pointed out that in the PD-L1 CPS ≥10 sub group population, the immunotherapy could obviously benefit the patients in tumor response rates (OR = 3.80, 95% CI: 1.89 to 7.61, P = 0.0002).
Conclusion:
For the treatment of advanced gastric esophageal cancer, the therapeutic efficacy of anti-PD-1/PD-L1 immunotherapy was superior to that of chemotherapy or palliative care.
Insights
Anti-PD-1/PD-L1 immunotherapy shows improved long-term survival for advanced gastric esophageal cancer patients. This treatment offers superior efficacy compared to traditional chemotherapy or palliative care, bringing new hope.
Area of Science:
- Oncology
- Immunotherapy
- Gastrointestinal Oncology
Background:
- Limited treatment options exist for advanced gastric esophageal cancer.
- Targeted therapies have largely failed, making immunotherapy a promising alternative.
- Immunotherapy, specifically targeting PD-1/PD-L1 pathways, offers new hope for patients.
Purpose of the Study:
- To analyze the safety and long-term survival of anti-PD-1/PD-L1 immunotherapy in advanced gastric esophageal cancer.
- To compare the efficacy of immunotherapy against control therapies.
Main Methods:
- A systematic search of studies on anti-PD-1/PD-L1 immunotherapy for advanced gastric esophageal cancer published before February 1, 2020.
- Comparison of survival outcomes (overall survival, progression-free survival) and adverse effects between immunotherapy and control groups.
- Meta-analysis was conducted to evaluate treatment efficacy.
Main Results:
- Anti-PD-1/PD-L1 immunotherapy significantly improved 12-month (OR=1.67) and 18-month survival (OR=1.98) compared to control.
- No significant difference in 3-month or 18-month survival rates was observed between groups.
- Objective response rates were not significantly different overall, but immunotherapy showed significant benefit in the PD-L1 CPS ≥10 subgroup (OR=3.80).
Conclusions:
- Anti-PD-1/PD-L1 immunotherapy demonstrates superior therapeutic efficacy for advanced gastric esophageal cancer compared to chemotherapy or palliative care.
- Immunotherapy offers a more effective treatment strategy for this patient population.
- Further research may focus on identifying patient subgroups that benefit most from immunotherapy.
Related Concept Videos
01:21Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...